Table 3.
Characteristics of prioritized patients according to ACLF-JM and MELD-Na.
| Characteristics of patients prioritized differently for liver transplantation within 28 days | |||||
|---|---|---|---|---|---|
| Both prioritized | ACLF-JM prioritized | MELD-Na prioritized | Not prioritized | p value∗ | |
| n | 2,186 | 450 | 450 | 6,990 | |
| Age (median [IQR]) | 56.0 [47.0, 62.0] | 62.0 [55.0, 67.0] | 50.0 [42.0, 56.8] | 59.0 [52.0, 64.0] | <0.001 |
| Male sex (%) | 1,336 (61.1) | 175 (38.9) | 326 (72.4) | 4,552 (65.1) | <0.001 |
| Death within 28 days (%) | 289 (13.2) | 59 (13.1) | 14 (3.1) | 90 (1.3) | <0.001 |
| ACLF (%) | <0.001 | ||||
| No ACLF | 172 (7.9) | 191 (42.4) | 162 (36.0) | 6,155 (88.1) | |
| ACLF-1 | 585 (26.8) | 95 (21.1) | 248 (55.1) | 720 (10.3) | |
| ACLF-2 | 792 (36.2) | 91 (20.2) | 39 (8.7) | 105 (1.5) | |
| ACLF-3 | 637 (29.1) | 73 (16.2) | 1 (0.2) | 10 (0.1) | |
| Disease | <0.001 | ||||
| Cirrhosis HCV | 165 (7.5) | 31 (6.9) | 39 (8.7) | 1,099 (15.7) | |
| NASH | 392 (17.9) | 147 (32.7) | 61 (13.6) | 1,479 (21.2) | |
| Cirrhosis alcohol-induced | 964 (44.1) | 130 (28.9) | 235 (52.2) | 1,768 (25.3) | |
| Cirrhosis other | 416 (19.0) | 68 (15.1) | 55 (12.2) | 988 (14.1) | |
| Cholestatic disease | 104 (4.8) | 41 (9.1) | 36 (8.0) | 638 (9.1) | |
| Metabolic disease | 56 (2.6) | 5 (1.1) | 13 (2.9) | 135 (1.9) | |
| Malignant/benign tumor | 39 (1.8) | 11 (2.4) | 7 (1.6) | 734 (10.5) | |
| Other | 50 (2.3) | 17 (3.8) | 4 (0.9) | 149 (2.1) | |
| MELD (median [IQR]) | 34.0 [29.0, 39.0] | 24.0 [21.0, 28.0] | 26.0 [23.0, 29.0] | 15.0 [11.0, 19.0] | <0.001 |
| MELD-Na (median [IQR]) | 33.0 [30.0, 38.0] | 25.0 [23.0, 26.0] | 28.0 [27.0, 30.0] | 15.0 [10.0, 20.0] | <0.001 |
| Life support dependent | 291 (13.3) | 84 (18.7) | 3 (0.7) | 50 (0.7) | <0.001 |
Clarification: JM-prioritized patients are not prioritized by MELD-Na, and vice versa.
ACLF, acute-on-chronic liver failure; ACLF-JM, acute-on-chronic liver failure joint model; MELD(-Na), model for end-stage liver disease(-sodium); NASH, non-alcoholic steatohepatitis.
∗
Difference tested between ACLF-JM-prioritized and MELD-Na-prioritized patients (chi-square and ANOVA tests).